胶质瘤中CA15-3、S100B和IGF-1的变化及其对治疗效果的预测价值。
Changes in CA15-3, S100B, and IGF-1 in glioma and their predictive value for treatment efficacy.
作者信息
Zhang Chunman, Wei Jianqiang, Wang Ying, Wang Ning, Xi Cong, Lv Maikou
机构信息
Military Surgery, Affiliated Hospital of Yan'an University Yan'an 716000, Shaanxi Province, China.
Second Department of Neurology, Baoji Central Hospital Baoji 721008, Shaanxi Province, China.
出版信息
Am J Transl Res. 2022 Oct 15;14(10):7002-7011. eCollection 2022.
OBJECTIVE
To analyze the changes of carbohydrate antigen 153 (CA15-3), S-100 calcium-binding protein B (S100B) and insulin-like growth factor-1 (IGF-1) in the treatment of patients with high-grade glioma and their predictive value for efficacy.
METHODS
In this retrospective the PG and CG study, 74 patients with glioma who were treated in the Affiliated Hospital of Yan'an University from January 2015 to January 2017 were labeled as the patient group (PG); the other 70 patients who underwent craniocerebral trauma surgery during the same period were selected as the control group (CG). The expressions of CA15-3, S100B and IGF-1 in the PG and CG were compared. The relationship between CA15-3, S100B, IGF-1, and the pathologic data of patients was analyzed. The expression differences of CA15-3, S100B, and IGF-1 were compared between low-grade glioma patients and high-grade glioma patients and their diagnostic value was analyzed. The values of CA15-3, S100B, and IGF-1 expression for predicting treatment efficacy were analyzed.
RESULTS
Expressions of CA15-3, S100B, and IGF-1 in glioma patients were markedly higher than those in the CG (P<0.0001). The proportion of grade III+IV patients with high expression of CA15-3, S100B, and IGF-1 was higher than in grade II patients (P<0.05), and the expressions of CA15-3, S100B and IGF-1 in low-grade glioma patients were lower than in high-grade glioma (P<0.01). The AUCs of CA15-3, S100B, and IGF-1 in differentiating different grades of glioma were 0.822, 0.722, and 0.768, respectively. Serum CA15-3, S100B and IGF-1 levels of the patients after treatment were significantly lower than those before treatment (P<0.0001). With the deterioration of clinical efficacy, serum levels of CA15-3, S100B, and IGF-1 gradually increased (P<0.05), and CA15-3, S100B and IGF-1 were positively correlated with therapeutic efficacy (P<0.05). AUCs of CA15-3, S100B, and IGF-1 for predicting the clinical efficacy in glioma patients were 0.824, 0.741, and 0.800, respectively.
CONCLUSION
CA15-3, S100B, and IGF-1 are highly expressed in patients with glioma. They are diagnostic indicators to distinguish patients with high-grade glioma, and have predictive value for treatment efficacy.
目的
分析糖类抗原153（CA15-3）、S-100钙结合蛋白B（S100B）和胰岛素样生长因子-1（IGF-1）在高级别胶质瘤患者治疗中的变化及其对疗效的预测价值。
方法
在这项回顾性病例对照研究中，将2015年1月至2017年1月在延安大学附属医院接受治疗的74例胶质瘤患者标记为患者组（PG）；选择同期70例行颅脑外伤手术的患者作为对照组（CG）。比较PG组和CG组中CA15-3、S100B和IGF-1的表达。分析CA15-3、S100B、IGF-1与患者病理数据之间的关系。比较低级别胶质瘤患者和高级别胶质瘤患者之间CA15-3、S100B和IGF-1的表达差异，并分析其诊断价值。分析CA15-3、S100B和IGF-1表达对预测治疗疗效的价值。
结果
胶质瘤患者中CA15-3、S100B和IGF-1的表达明显高于CG组（P<0.0001）。CA15-3、S100B和IGF-1高表达的Ⅲ+Ⅳ级患者比例高于Ⅱ级患者（P<0.05），低级别胶质瘤患者中CA15-3、S100B和IGF-1的表达低于高级别胶质瘤患者（P<0.01）。CA15-3、S100B和IGF-1区分不同级别胶质瘤的曲线下面积（AUC）分别为0.822、0.722和0.768。治疗后患者血清CA15-3、S100B和IGF-1水平明显低于治疗前（P<0.0001）。随着临床疗效的恶化，血清CA15-3、S100B和IGF-1水平逐渐升高（P<0.05），且CA15-3、S100B和IGF-1与治疗疗效呈正相关（P<0.05）。CA15-3、S100B和IGF-1预测胶质瘤患者临床疗效的AUC分别为0.824、0.741和0.800。
结论
CA15-3、S100B和IGF-1在胶质瘤患者中高表达。它们是区分高级别胶质瘤患者的诊断指标，对治疗疗效具有预测价值。
Zotero 插件